The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment

Pancreatic ductal adenocarcinoma (PDAC) is a major concern for health care systems worldwide, since its mortality remains unaltered despite the surge in cutting-edge science. The EPH/ephrin signaling system was first investigated in the 1980s. EPH/ephrins have been shown to exert bidirectional signaling and cell-to-cell communication, influencing cellular morphology, adhesion, migration and invasion. Recent studies have highlighted the critical role of the EPH/ephrin system in various physiologic processes, including cellular proliferation, survival, synaptic plasticity and angiogenesis. Thus, it has become evident that the EPH/ephrin signaling system may have compelling effects on cell homeostasis that contribute to carcinogenesis. In particular, the EPH/ephrins have an impact on pancreatic morphogenesis and development, whereas several EPHs and ephrins are altered in PDAC. Several clinical and preclinical studies have attempted to elucidate the effects of the EPH/ephrin pathway, with multilayered effects on PDAC development. These studies have highlighted its highly promising role in the diagnosis, prognosis and therapeutic management of PDAC. The aim of this review is to explore the obscure aspects of the EPH/ephrin system concerning the development, physiology and homeostasis of the pancreas.

[1]  N. Navin,et al.  Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer , 2022, Nature Cancer.

[2]  Axel Behrens,et al.  The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma , 2022, Oncogene.

[3]  B. Vincent,et al.  Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity , 2022, Cell reports. Medicine.

[4]  S. Theocharis,et al.  Angiogenesis in gastrointestinal stromal tumors: From bench to bedside , 2022, World journal of gastrointestinal oncology.

[5]  Shun Xu,et al.  EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma. , 2022, International immunopharmacology.

[6]  T. LaFramboise,et al.  The Ephrin B2 Receptor Tyrosine Kinase is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's Neoplasia. , 2022, Gastroenterology.

[7]  Jun Liu,et al.  Metalloprotease ADAM9 cleaves ephrin-B ligands and differentially regulates Wnt and mTOR signaling downstream of Akt kinase in colorectal cancer cells , 2022, The Journal of biological chemistry.

[8]  Stamatios A. Theocharis,et al.  The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity , 2022, Cancers.

[9]  S. Karam,et al.  EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment , 2022, Nature Communications.

[10]  S. Theocharis,et al.  The EPH/Ephrin System in Bone and Soft Tissue Sarcomas’ Pathogenesis and Therapy: New Advancements and a Literature Review , 2022, International journal of molecular sciences.

[11]  G. O'Keefe,et al.  A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers , 2022, Investigational New Drugs.

[12]  T. Okazaki,et al.  Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. , 2022, Immunity.

[13]  M. Gazouli,et al.  Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? , 2022, International journal of molecular sciences.

[14]  S. Theocharis,et al.  Utilizing Exosomal-EPHs/Ephrins as Biomarkers and as a Potential Platform for Targeted Delivery of Therapeutic Exosomes , 2022, International journal of molecular sciences.

[15]  A. Masamune,et al.  Clinical features and prognostic impact of asymptomatic pancreatic cancer , 2022, Scientific Reports.

[16]  S. Theocharis,et al.  The EPH/Ephrin System in Colorectal Cancer , 2022, International journal of molecular sciences.

[17]  S. Theocharis,et al.  The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management , 2022, International journal of molecular sciences.

[18]  A. Califano,et al.  Notch-mediated Ephrin signaling disrupts islet architecture and β cell function , 2022, JCI insight.

[19]  Abid Ali,et al.  Mechanistic and therapeutic implications of EphA‐4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease , 2022, The European journal of neuroscience.

[20]  I. Mitroulis,et al.  Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy , 2022, Cancers.

[21]  D. Cornelison,et al.  Eph/Ephrin-Based Protein Complexes: The Importance of cis Interactions in Guiding Cellular Processes , 2022, Frontiers in Molecular Biosciences.

[22]  N. Hiraoka,et al.  Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5 , 2021, British Journal of Cancer.

[23]  M. Henkemeyer,et al.  Key role for EphB2 receptor in kidney fibrosis , 2021, Clinical science.

[24]  S. Theocharis,et al.  The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread , 2021, International journal of molecular sciences.

[25]  L. Qin,et al.  The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives , 2021, Signal Transduction and Targeted Therapy.

[26]  D. Mukhopadhyay,et al.  Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer , 2021, Cancers.

[27]  I. Mitroulis,et al.  Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy , 2021, Cancers.

[28]  Kimberly R. Jordan,et al.  Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer , 2021, Cancer Research.

[29]  Felicia L. Lenzo,et al.  Immune profiling and immunotherapeutic targets in pancreatic cancer , 2021, Annals of translational medicine.

[30]  Yafeng Wu,et al.  Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and miRNAs. , 2020, Small.

[31]  Xianjun Yu,et al.  Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma , 2020, Journal of Hematology & Oncology.

[32]  L. Ren,et al.  Serum Exo-EphA2 as a Potential Diagnostic Biomarker for Pancreatic Cancer , 2020, Pancreas.

[33]  Min Su,et al.  Targeting EphA2 in cancer , 2020, Journal of Hematology & Oncology.

[34]  M. Karamouzis,et al.  Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy , 2020, World journal of gastrointestinal oncology.

[35]  Y. Miao,et al.  EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[36]  O. Britanova,et al.  B cells, plasma cells and antibody repertoires in the tumour microenvironment , 2020, Nature Reviews Immunology.

[37]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[38]  Zihua Chen,et al.  EphA2‐to‐YAP pathway drives gastric cancer growth and therapy resistance , 2020, International journal of cancer.

[39]  D. Wilkinson,et al.  A morphogenetic EphB/EphrinB code controls hepatopancreatic duct formation , 2019, Nature Communications.

[40]  W. Kamoun,et al.  Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[41]  J. Tobias,et al.  Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). , 2019, The Journal of clinical investigation.

[42]  I. Hyodo,et al.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors , 2019, Journal of Immunotherapy for Cancer.

[43]  J. Conejo-Garcia.  Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer. , 2019, The Journal of clinical investigation.

[44]  V. Balachandran,et al.  Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. , 2019, Gastroenterology.

[45]  Kimberly R. Jordan,et al.  Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination , 2019, Clinical Cancer Research.

[46]  Wei Wu,et al.  EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer , 2018, Cell Death & Disease.

[47]  R. Searcy,et al.  IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer , 2018, Cancer Immunology Research.

[48]  P. Grippo,et al.  Pancreatic cancer subtypes: a roadmap for precision medicine , 2018, Annals of medicine.

[49]  M. Seiki,et al.  Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer , 2017, Cell Death and Disease.

[50]  A. Maitra,et al.  The role of stromal cancer-associated fibroblasts in pancreatic cancer , 2017, Journal of Hematology & Oncology.

[51]  W. Baze,et al.  Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA) , 2017, Molecular Cancer Therapeutics.

[52]  A. Jimeno,et al.  Ephrin‐B2 overexpression predicts for poor prognosis and response to therapy in solid tumors , 2017, Molecular carcinogenesis.

[53]  M. Pasca di Magliano,et al.  Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer , 2016, Gut.

[54]  C. N. Coleman,et al.  Radiotherapy: Changing the Game in Immunotherapy. , 2016, Trends in cancer.

[55]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[56]  D. Allman,et al.  Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. , 2016, Cancer discovery.

[57]  D. Bar-Sagi,et al.  IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. , 2016, Cancer discovery.

[58]  A. V. Nguyen,et al.  Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. , 2016, Cancer discovery.

[59]  A. Kania,et al.  Mechanisms of ephrin–Eph signalling in development, physiology and disease , 2016, Nature Reviews Molecular Cell Biology.

[60]  D. Tuveson,et al.  BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages , 2015, Nature Communications.

[61]  T. Shichinohe,et al.  Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice , 2015, Oncotarget.

[62]  D. Piston,et al.  EphA4 Receptor Forward Signaling Inhibits Glucagon Secretion From α-Cells , 2015, Diabetes.

[63]  M. Croft,et al.  4-1BB Ligand Signaling to T Cells Limits T Cell Activation , 2015, The Journal of Immunology.

[64]  S. Theocharis,et al.  The role of ephrins' receptors and ephrins' ligands in normal placental development and disease , 2014, Expert opinion on therapeutic targets.

[65]  C. Roland,et al.  A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. , 2013, Gastroenterology.

[66]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[67]  J. Wright,et al.  Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. , 2013, The oncologist.

[68]  E. Patsouris,et al.  Ephrins and pain , 2013, Expert opinion on therapeutic targets.

[69]  O. Govaere,et al.  Molecular markers associated with outcome and metastasis in human pancreatic cancer , 2012, Journal of experimental & clinical cancer research : CR.

[70]  L. Tran,et al.  Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development , 2012, Molecular Cancer Therapeutics.

[71]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[72]  Zhaoyu Li,et al.  Overexpression of the B-type Eph and ephrin genes correlates with progression and pain in human pancreatic cancer. , 2012, Oncology letters.

[73]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[74]  J. Schug,et al.  Transcriptomes of the major human pancreatic cell types , 2011, Diabetologia.

[75]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[76]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[77]  F. C. Pan,et al.  Pancreas organogenesis: From bud to plexus to gland , 2011, Developmental dynamics : an official publication of the American Association of Anatomists.

[78]  Diana C. Chong,et al.  Epithelial dynamics of pancreatic branching morphogenesis , 2010, Development.

[79]  P. Gill,et al.  Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis , 2010, BMC Cancer.

[80]  Elena B. Pasquale,et al.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.

[81]  K. Dimakopoulou,et al.  Clinical Significance of Ephrin (Eph)-A1, -A2, -A4, -A5 and -A7 Receptors in Pancreatic Ductal Adenocarcinoma , 2010, Pathology & Oncology Research.

[82]  A. Meola,et al.  Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer , 2010, Journal of oncology.

[83]  P. Bosma,et al.  Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. , 2009, World journal of gastroenterology.

[84]  Elena B Pasquale,et al.  Eph-Ephrin Bidirectional Signaling in Physiology and Disease , 2008, Cell.

[85]  C. Hall,et al.  α2-Chimaerin interacts with EphA4 and regulates EphA4-dependent growth cone collapse , 2007, Proceedings of the National Academy of Sciences.

[86]  Alessandro Filosa,et al.  EphA4-Dependent Axon Guidance Is Mediated by the RacGAP α2-Chimaerin , 2007, Neuron.

[87]  W. Wurst,et al.  EphA-Ephrin-A-Mediated β Cell Communication Regulates Insulin Secretion from Pancreatic Islets , 2007, Cell.

[88]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[89]  H. Friess,et al.  Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. , 2006, Gastroenterology.

[90]  Peter M. Jones,et al.  MIN6 β-cell-β-cell interactions influence insulin secretory responses to nutrients and non-nutrients , 2006 .

[91]  P. Vanderhaeghen,et al.  Eph receptors and their ephrin ligands are expressed in developing mouse pancreas. , 2006, Gene expression patterns : GEP.

[92]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[93]  Donna J. Webb,et al.  FAK–Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly , 2004, Nature Cell Biology.

[94]  C. Wollheim,et al.  Mitochondrial function in normal and diabetic β-cells , 2001, Nature.

[95]  E. Pasquale,et al.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization , 2000, Oncogene.